Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating

On June 3, Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while keeping an Overweight rating on the shares. The firm adjusted its price target after management lowered its EPS outlook for 2025.

The company reported fiscal second-quarter results on May 1, with revenue increasing 4.5% year-over-year to $5.3 billion. Despite the growth, revenue missed the consensus by $80.64 million.

Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Amid EPS Outlook Downgrade 

A surgeon performing a procedure in an operating room using a medical device supplied by the company.

Becton, Dickinson, and Company (NYSE:BDX) is facing the impact of tariffs and management estimates it to be around $0.25 per share for the fiscal year 2025. As a result, the company reduced its full-year EPS outlook from a range of $14.30 to $14.60 to a range of $14.06 to $14.34.

Becton, Dickinson, and Company (NYSE:BDX) is a global medical technology company that develops, manufactures, and sells a broad range of medical supplies. It operates through three main business segments including BD Medical, BD Life Sciences, and BD interventional.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.